Literature DB >> 30057224

Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.

Jamal S Rana1, Jennifer Y Liu2, Howard H Moffet2, Susan H Boklage3, Irfan Khan4, Andrew J Karter2.   

Abstract

The relevance of low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C) goals for primary prevention of atherosclerotic cardiovascular disease (ASCVD) among patients with diabetes was assessed. This retrospective cohort study included patients with type 2 diabetes, age 21 to 90years, taking statins, with no history of ASCVD as of January 1, 2006, in Kaiser Permanente Northern California, an integrated healthcare delivery system. Multivariate cox models were utilized to estimate hazard ratios (HRs) for incident ASCVD events by achieved LDL-C and non-HDL-C levels with adjustment for potential confounders. Incident ASCVD events were defined as a composite of myocardial infarction, ischemic stroke, or coronary heart disease death. A cohort of 62,428 patients, with mean age of 64.1years, 46.9% women, and mean follow-up of 6.0 years, was identified. After adjustment, the risk of incident ASCVD for these statin-treated patients was monotonically lower with decreasing achieved LDL-C levels (p<0.0001 for trend) and non-HDL-C levels (p <0.0001 for trend). Relative to achieved LDL-C ≥130 mg/dl, LDL-C <50 mg/dl had HR = 0.58 (95% confidence interval 0.49 to 0.69). Relative to achieved non-HDL-C ≥160mg/dl, non-HDL-C <80 mg/dl had HR = 0.59 (95% confidence interval 0.51 to 0.68). In a large cohort of statin-treated diabetic patients without ASCVD, a monotonically lower risk of incident ASCVD events was associated with lower achieved lipid levels. These findings support the use of LDL-C ornon-HDL-C treatment goals for ASCVD primary prevention in diabetic patients.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30057224     DOI: 10.1016/j.amjcard.2018.05.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies.

Authors:  Haider J Warraich; Jamal S Rana
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

2.  Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease.

Authors:  Mee Kyoung Kim; Kyungdo Han; Han Na Joung; Ki-Hyun Baek; Ki-Ho Song; Hyuk-Sang Kwon
Journal:  Cardiovasc Diabetol       Date:  2019-10-22       Impact factor: 9.951

3.  Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE).

Authors:  Carlos I Ponte-Negretti; Fernando S Wyss; Daniel Piskorz; Raul D Santos; Raul Villar; Alberto Lorenzatti; Patricio López-Jaramillo; Peter P. Toth; A Juan J Amaro; Alfonso K Rodrigo; Fernando Lanas; Miguel Urina-Triana; Jofre Lara; T Osiris Valdés; José R Gomez-Mancebo; Alfonso Bryce; Leonardo Cobos S; Adriana Puente-Barragan; Vladimir E Ullauri-Solórzano; Felix A Medina-Palomino; Alfredo F Lozada; Maritza Duran; Percy Berrospi; David Miranda; Juan J Badimon; J José R González; Peter Libby
Journal:  Arch Cardiol Mex       Date:  2022-01-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.